Antibiotics Market Analysis Report By Drug Class, By Action Mechanism And Segment Forecasts From 2021 To 2028

Report ID: MN17617512  |  Published: May 2021  |  No of Pages: 120
Format: Electronic (PDF)  |  Industry: Pharmaceuticals


Regarding the report published, the global antibiotics market size was prized by USD 40.7 billion in 2020. It is estimated to witness a 4.5% CAGR from 2021 to 2028.


The increasing occurrences of infectious sicknesses and sympathetic legislation by the government are the most important stimulators of the market for antibiotics. Furthermore, a rise in antibiotic resistance disease, because of mistreatment or overeating of antibiotics, is estimated to change the recommendation patterns, to new treatments, to take care of bacterial infectivity.

The augmented hard work of the pharmaceutical manufacturing companies, for the advancement of innovative treatments to take care of infectious sicknesses, is estimated to impel the market, during the forecast period. The introduction of the new-fangled antibiotic medicines is anticipated to maintain the expansion of the market, all through the estimated time. Due to the rising frequency of infectious illnesses, the requirement for antibiotics is considerably growing.


The greater frequency of infectious sicknesses, for example, tuberculosis, pneumonia, malaria, and lower respiratory infections is, furthermore powering the enlargement of the market. Furthermore, the growing figure of public-private partnerships, in which financial support and modern R&D methods are provided by the public organizations, to the companies developing antibiotics, is estimated to increase the list of the products.

Effect of Covid-19

Several remedial procedures are being tracked through the world, to search for a dependable medication for Covid-19. One route of action comprises the utilization of Hydroxychloroquine; whereas a subsequent medication route concentrates on making use of antiviral medicines, which are utilized in the infection administration of HIV. Equally, these methods have gush demand for highly developed anti-malarial and antiviral medicines. Currently, the world health organization (WHO) has neither approved any of these methods; nor they have mentioned, if one is superior to the other.

Action Mechanism Insight

Cell wall synthesis inhibitors held a 52.1% share in 2020 and led the antibiotics market. It is expected to uphold its leadership, all over the forecast period. High-pitched utilization, as stated by the treatment model and major financial support by the government, is the important thing moving the section. Cell wall synthesis inhibitors are extensively used antibiotics, since they are distinguished by the extensive range of activities, in opposition to gram-positive as well as negative microorganisms. Due to an escalation in research actions, together with government financial support, cell wall synthesis inhibitors are projected to observe, major enlargement, during the forecast period.

Owing to the growth in the R&D projects and several products introduced, the RNA synthesis inhibitors section is likely to observe major expansion, during the forecast period.

Drug Class Insight

By the reason of maximum recommendations as well as the biggest number of general manufacturing companies, operational in the field, penicillin held the 23.9% share in 2020. It is anticipated to lead the antibiotic market during the period of the forecast. These drugs are the most preferred in taking care of diverse types of illnesses, for example, ear infections, bronchitis, pharyngitis, gonorrhea, and skin infections.


Cephalosporin appeared like the subsequent major drug class section, following Penicillin, and is estimated to increase by a large proportion, all through the forecast period. The fluoroquinolone and cephalosporin sections are likely to develop by a major percentage, during the forecast period. The enlargement of these segments can be credited to the commercialization of the new-fangled medicines, in the anticipated period.

Due to the forthcoming new treatments; those are estimated to start on during the forecast period, the others sector is likely to rise by the highest speed, during the approaching years. This division comprises a range of presented classes of antibiotics, in addition to a few recently developed antibiotic medicines, for example, oxazolidinone, imidazoles, tetracyclines, amphenicols, lincosamides, and the mixture drugs. The commercialization of zoliflodacin, gepotidacin, ridinilazole, and iclaprim, is expected to increase the progress of the market throughout the anticipated period.

Regional Insight

The Asia Pacific retained the major 45.2% share in 2020 and is anticipated to record a momentous development percentage, throughout the forecast period. This can be credited to the rise in the occurrences of infectious diseases, the excessive utilization of antibiotics, and increasing government inventiveness to make available the new treatments, to take care of drug-resistant diseases.

Furthermore, the existence of general companies is adding to the expansion of the local market. China, as well as India, is the major market for antibiotics, within the region. Surplus expenditure of antibiotics and free sales are the input factors, sustaining the expansion of the market, within these nations.

In 2020, North America appeared like the subsequent major local market for antibiotics. It was tracked by Europe. Europe and North America, jointly detained above 48.0% share, in 2020. These markets are extremely synchronized by strong healthcare infrastructure.

The increasing occurrences of transmittable sicknesses along with the growing expenses on healthcare by the governments are the important factors, stirring the North American market for antibiotics. The U.S. government is taking on a variety of actions, together with an antibiotic stewardship plan, and encourages the R&D actions of modern therapies, to keep under control infectious diseases.


The small & medium-sized biotech manufacturing companies are mostly concerned with the improvement of the new treatment. These companies promote the goods that are particularly aimed at the system of bacterial confrontation. Whereas, others comprise the companies having clinical phase possessions that are estimated to enter the near future.

Some of the companies for antibiotics market are:

• Nabriva Therapeutics plc
• Tetra phase Pharmaceuticals
• Melinta Therapeutics
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Spero Therapeutics
• Paratek Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd.
• Pfizer Inc.
• Allergan plc (AbbVie)

Report Scope

Report Attribute


The market size value in 2021

USD 41.54 billion

The revenue forecast in 2028

USD 57.99 billion

Growth Rate

CAGR of 4.5% from 2021 to 2028

The base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Action mechanism, drug class, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; China; Japan; Thailand; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa

Key companies profiled

Merck & Co., Inc.; Allergan plc; Pfizer Inc.; Melinta Therapeutics; Basilea Pharmaceutica Ltd.; Tetraphase Pharmaceuticals

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. 

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For this study, Million Insights has segmented the global antibiotics market report based on action mechanism, drug class, and region:

• Action Mechanism Outlook (Revenue, USD Million, 2017 - 2028)
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • DNA Synthesis Inhibitors
    • RNA Synthesis Inhibitors
    • Mycolic Acid Inhibitors
    • Others

• Drug Class Outlook (Revenue, USD Million, 2017 - 2028)
    • Cephalosporin
    • Penicillin
    • Fluoroquinolone
    • Macrolide
    • Carbapenem
    • Aminoglycoside
    • Sulfonamide
    • 7-ACA
    • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
    • The Asia Pacific
        • India
        • China
        • Japan
        • Thailand
        • South Korea
    • Latin America
        • Argentina
        • Brazil
        • Mexico
    • Middle East & Africa
        • Saudi Arabia
        • UAE
        • South Africa

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
Connect With Expert
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service

Get a Free Sample

FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...